Prognostic factors in soft tissue sarcoma

Danish Medical Journal

Volumn 61, Issue 11, 2014, Pages

  Maretty Nielsen, Katja ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; HEMOGLOBIN; INTERLEUKIN 1; INTERLEUKIN 6; SODIUM; BIOLOGICAL MARKER;

AGE; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGISTRY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; CELL COMPARTMENTALIZATION; CLINICAL FEATURE; COMORBIDITY; FOLLOW UP; GENDER; HUMAN; HYPOALBUMINEMIA; HYPONATREMIA; MEDICAL LITERATURE; MEDICAL RECORD; MEDICAL RESEARCH; NEUTROPHIL LYMPHOCYTE RATIO; OUTCOME ASSESSMENT; POPULATION RESEARCH; PROGNOSTIC ASSESSMENT; PUBLICATION; SOFT TISSUE SARCOMA; TUMOR VOLUME; VALIDATION PROCESS; ADULT; AGED; COHORT ANALYSIS; DENMARK; FEMALE; INCIDENCE; MALE; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; REGISTER; REPRODUCIBILITY; RISK FACTOR; SARCOMA; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COHORT STUDIES; COMORBIDITY; DENMARK; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; REGISTRIES; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SARCOMA;

EID: 84930702683     PISSN: None     EISSN: 22451919     Source Type: Journal    
DOI: None     Document Type: Article

References (221)

1. Sundhedsstyrelsen. Cancerregisteret 2008.
2. Blay JY, Le Cesne A. Adjuvant chemotherapy in localized soft tissue sarcomas: Still not proven. Oncologist. 2009; 14(10): 1013-1020.
3. Scurr M. Histology-driven chemotherapy in soft tissue sarcomas. Curr Treat Options Oncol. 2011;12(1):32-45.
4. Woll PJ, Reichardt P, Le Cesne A, et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): A multicentre randomised controlled trial. Lancet Oncol. 2012;13(10):1045- 1054.
5. Bauer HC, Trovik CS, Alvegard TA, et al. Monitoring referral and treatment in soft tissue sarcoma: Study based on 1,851 patients from the Scandinavian sarcoma group register. Acta OrthopScand. 2001;72(2):150-159.
6. Bauer HC, Ahlén J, Alvegard TA, et al. The Scandinavian sarcoma group register 1986-2008. Acta Orthop ScandSuppl. 2009;80(334): 13-14.
7. Weitz J, Antonescu CR, Brennan MF. Localized extremity soft tissue sarcoma: Improved knowledge with unchanged survival over time. J Clin Oncol. 2003;21(14):2719-2725.
8. Zagars GK, Ballo MT, Pisters PW, et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: An analysis of 1225 patients. Cancer. 2003;97(10):2530-2543.
9. Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol. 2002;20(3):791-796.
10. Gutierrez JC, Perez EA, Franceschi D, Moffat FL, Jr, Livingstone AS, Koniaris LG. Outcomes for soft-tissue sarcoma in 8249 cases from a large state cancer registry. J Surg Res. 2007; 141(1): 105-114.
11. Maki RG, Moraco N, Antonescu CR, et al. Toward better soft tissue sarcoma staging: Building on american joint committee on cancer staging systems versions 6 and 7. Ann Surg Oncol. 2013;20(11):3377-3383.
12. Coindre JM. Grading of soft tissue sarcomas: Review and update. Arch Pathol Lab Med. 2006;130(10):1448-1453.
13. Trovik CS, Bauer HC, Alvegard TA, et al. Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically-treated patients from the Scandinavian sarcoma group register. EurJ Cancer. 2000;36(6):710-716.
14. Alho A, Alvegard TA, Berlin O, et al. Surgical margin in soft tissue sarcoma, the Scandinavian sarcoma group experience. Acta OrthopScand. 1989;60(6):687-692.
15. Stotter AT, A'Hern RP, Fisher C, Mott AF, Fallowfield ME, Westbury G. The influence of local recurrence of extremity soft tissue sarcoma on metastasis and survival. Cancer. 1990; 65(5): 1119-1129.
16. Saddegh MK, Lindholm J, Lundberg A, Nilsonne U, Kreicbergs A. Staging of soft-tissue sarcomas, prognostic analysis of clinical and pathological features. J Bone Joint Surg Br. 1992;74(4):495-500.
17. Lintz F, Moreau A, Odri GA, Waast D, Maillard O, Gouin F. Critical study of resection margins in adult soft-tissue sarcoma surgery. Orthop TraumatolSurg Res. 2012;98(4 Suppl):S9-18.
18. Alkis N, Muallaoglu S, Kocer M, et al. Primary adult soft tissue sarcomas: Analysis of 294 patients. Med Oncol. 2011;28(1):391-396.
19. Dagan R, Indelicato DJ, McGee L, et al. The significance of a marginal excision after preoperative radiation therapy for soft tissue sarcoma of the extremity. Cancer. 2012;118(12):3199-3207.
20. Gronchi A, Casali PG, Mariani L, et al. Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: A series of patients treated at a single institution. J Clin Oncol. 2005;23(1):96-104.
21. Gustafson P. Soft tissue sarcoma, epidemiology and prognosis in 508 patients. Acta Orthop Scand Suppl. 1994;259:1-31.
22. Guillou L, Coindre JM, Bonichon F, et al. Comparative study of the national cancer institute and french federation of cancer centers sarcoma group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol. 1997;15(l):350-362.
23. Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996; 14(5): 1679-1689.
24. Koea JB, Leung D, Lewis JJ, Brennan MF. Histopathologic type: An independent prognostic factor in primary soft tissue sarcoma of the extremity? Ann Surg Oncol. 2003;10(4):432-440.
25. Lahat G, Tuvin D, Wei C, et al. New perspectives for staging and prognosis in soft tissue sarcoma. Ann Surg Oncol. 2008;15(10):2739-2748.
26. Biau DJ, Ferguson PC, Turcotte RE, et al. Adverse effect of older age on the recurrence of soft tissue sarcoma of the extremities and trunk. J Clin Oncol. 2011;29(30):4029-4035.
27. Ueda T, Aozasa K, Tsujimoto M, et al. Multivariate analysis for clinical prognostic factors in 163 patients with soft tissue sarcoma. Cancer. 1988;62(7):1444-1450.
28. Saithna A, Pynsent PB, Grimer RJ. Retrospective analysis of the impact of symptom duration on prognosis in soft tissue sarcoma. Int Orthop. 2008;32(3):381-384.
29. Urakawa H, Tsukushi S, Arai E, et al. Association of short duration from initial symptoms to specialist consultation with poor survival in soft-tissue sarcomas. Am J Clin Oncol. 2013;00(00):l-6 [Epub ahead of print]
30. Rougraff BT, Davis K, Lawrence J. Does length of symptoms before diagnosis of sarcoma affect patient survival? Clin Orthop Relat Res. 2007;462:181-189.
31. Nakamura T, Matsumine A, Matsubara T, Asanuma K, Uchida A, Sudo A. The symptom-to-diagnosis delay in soft tissue sarcoma influence the overall survival and the development of distant metastasis. J Surg Oncol. 2011;104(7):771-775.
32. Rougraff BT, Lawrence J, Davis K. Length of symptoms before referral: Prognostic variable for high-grade soft tissue sarcoma? Clin Orthop Relat Res. 2012;470(3):706-711.
33. Tomita Y, Kuratsu S, Naka N, et al. A staging system for soft- tissue sarcoma and its evaluation in relation to treatment. Int J Cancer. 1994;58(2):168-173.
34. Rydholm A, Berg NO, Gullberg B, Persson BM, Thorngren KG. Prognosis for soft-tissue sarcoma in the locomotor system. A retrospective population-based follow-up study of 237 patients. Acta Pathol Microbiol Immunol Scand A. 1984;92(5):375-386.
35. Stojadinovic A, Leung DH, Hoos A, Jaques DP, Lewis JJ, Brennan MF. Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg. 2002;235(3):424-434.
36. Gronchi A, Lo Vullo S, Colombo C, et al. Extremity soft tissue sarcoma in a series of patients treated at a single institution: Local control directly impacts survival. Ann Surg. 2010;251(3):506-511.
37. Stojadinovic A, Leung DH, Allen P, Lewis JJ, Jaques DP, Brennan MF. Primary adult soft tissue sarcoma: Time-dependent influence of prognostic variables. J Clin Oncol. 2002;20(21):4344-4352.
38. Jebsen NL, Trovik CS, Bauer HC, et al. Radiotherapy to improve local control regardless of surgical margin and malignancy grade in extremity and trunk wall soft tissue sarcoma: A Scandinavian sarcoma group study. IntJ Radiat Oncol Biol Phys. 2008;71(4): 1196-1203.
39. Biau DJ, Ferguson PC, Chung P, et al. Local recurrence of localized soft tissue sarcoma: A new look at old predictors. Cancer. 2012;118(23):5867-5877.
40. Lewis JJ, Leung D, Heslin M, Woodruff JM, Brennan MF. Association of local recurrence with subsequent survival in extremity soft tissue sarcoma. J Clin Oncol. 1997;15(2):646-652.
41. Parsons HM, Habermann EB, Tuttle TM, Al-Refaie WB. Conditional survival of extremity soft-tissue sarcoma: Results beyond the staging system. Cancer. 2011;117(5):1055-1060.
42. Rydholm A, Gustafson P. Should tumor depth be included in prognostication of soft tissue sarcoma? BMC Cancer. 2003;3(1):17-21.
43. Gaynor JJ, Tan CC, Casper ES, et al. Refinement of clinico- pathologic staging for localized soft tissue sarcoma of the extremity: A study of 423 adults. J Clin Oncol. 1992;10(8):1317-1329.
44. Bell RS, O’sullivan B, Liu FF, et al. The surgical margin in soft- tissue sarcoma. J Bone Joint Surg Am. 1989;71(3):370-375.
45. Peabody TD, Simon MA. Principles of staging of soft-tissue sarcomas. Clin Orthop Relat Res. 1993;289(289):19-31.
46. Rooser B, Attewell R, Berg NO, Rydholm A. Prognostication in soft tissue sarcoma. A model with four risk factors. Cancer. 1988;61(4):817-823.
47. Eilber FC, Rosen G, Nelson SD, et al. High-grade extremity soft tissue sarcomas: Factors predictive of local recurrence and its effect on morbidity and mortality. Ann Surg. 2003;237(2):218-226.
48. Broders AC. Squamous-cell epithelioma of the lip: A study of five hundred and thirty-seven cases. J Am Med Assoc. 1920; 74(10):656-664.
49. Gustafson P, Akerman M, Alvegard TA, et al. Prognostic information in soft tissue sarcoma using tumour size, vascular invasion and microscopic tumour necrosis-the SIN- system. EurJ Cancer. 2003;39(11):1568-1576.
50. van Unnik JA, Coindre JM, Contesso C, et al. Grading of soft tissue sarcomas: Experience of the EORTC soft tissue and bone sarcoma group. EurJ Cancer. 1993;29A(15):2089-2093.
51. Jensen OM, Hogh J, Ostgaard SE, Nordentoft AM, Sneppen O. Histopathological grading of soft tissue tumours, prognostic significance in a prospective study of 278 consecutive cases. J Pathol. 1991;163(1):19-24.
52. Costa J, Wesley RA, Glatstein E, Rosenberg SA. The grading of soft tissue sarcomas, results of a clinicohistopathologic correlation in a series of 163 cases. Cancer. 1984;53(3):530-541.
53. Trojani M, Contesso G, Coindre JM, et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. IntJ Cancer. 1984;33(1):37-42.
54. Berlin O, Stener B, Angervall L, Kindblom LG, Markhede G, Oden A. Surgery for soft tissue sarcoma in the extremities. A multivariate analysis of the 6-26-year prognosis in 137 patients. Acta Orthop Scand. 1990;61(6):475-486.
55. Brooks AD, Heslin MJ, Leung DH, Lewis JJ, Brennan MF. Superficial extremity soft tissue sarcoma: An analysis of prognostic factors. Ann Surg Oncol. 1998;5(1):41-47.
56. Cahlon O, Spierer M, Brennan MF, Singer S, Alektiar KM. Long-term outcomes in extremity soft tissue sarcoma after a pathologically negative re-resection and without radiotherapy. Cancer. 2008;112(12):2774-2779.
57. Collin CF, Friedrich C, Godbold J, Hajdu S, Brennan MF. Prognostic factors for local recurrence and survival in patients with localized extremity soft-tissue sarcoma. Semin Surg Oncol. 1988;4(1):30-37.
58. LeVay J, O’sullivan B, Catton C, et al. Outcome and prognostic factors in soft tissue sarcoma in the adult. IntJ Radiat Oncol Biol Phys. 1993;27(5): 1091-1099.
59. Liu CY, Yen CC, Chen WM, et al. Soft tissue sarcoma of extremities: The prognostic significance of adequate surgical margins in primary operation and reoperation after recurrence. Ann Surg Oncol. 2010;17(8):2102-2111.
60. Alektiar KM, Velasco J, Zelefsky MJ, Woodruff JM, Lewis JJ, Brennan MF. Adjuvant radiotherapy for margin-positive high- grade soft tissue sarcoma of the extremity. Int J Radiat Oncol Biol Phys. 2000;48(4): 1051-1058.
61. Coindre JM, Terrier P, Bui NB, et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the french federation of cancer centers sarcoma group. J Clin Oncol. 1996;14(3):869-877.
62. Felderhof JM, Creutzberg CL, Putter H, et al. Long-term clinical outcome of patients with soft tissue sarcomas treated with limb-sparing surgery and postoperative radiotherapy. Acta Oncol. 2012;52(4):745-752.
63. Heslin MJ, Woodruff J, Brennan MF. Prognostic significance of a positive microscopic margin in high-risk extremity soft tissue sarcoma: Implications for management. J Clin Oncol. 1996;14(2):473-478.
64. Kim YB, Shin KH, Seong J, et al. Clinical significance of margin status in postoperative radiotherapy for extremity and truncal soft-tissue sarcoma. IntJ Radiat Oncol Biol Phys. 2008;70(1): 139-144.
65. Matsubara T, Kusuzaki K, Matsumine A, Nakamura T, Sudo A. Can a less radical surgery using photodynamic therapy with acridine orange be equal to a wide-margin resection? Clin Orthop Relat Res. 2013;471(3):792-802.
66. McGee L, Indelicato DJ, Dagan R, et al. Long-term results following postoperative radiotherapy for soft tissue sarcomas of the extremity. IntJ Radiat Oncol Biol Phys. 2012;84(4): 1003-1009.
67. McKee MD, Liu DF, Brooks JJ, Gibbs JF, Driscoll DL, Kraybill WG. The prognostic significance of margin width for extremity and trunk sarcoma. J Surg Oncol. 2004;85(2):68-76.
68. Novais EN, Demiralp B, Alderete J, Larson MC, Rose PS, Sim FH. Do surgical margin and local recurrence influence survival in soft tissue sarcomas? Clin Orthop Relat Res. 2010;468(11):3003-3011.
69. Ravaud A, Bui NB, Coindre JM, et al. Prognostic variables for the selection of patients with operable soft tissue sarcomas to be considered in adjuvant chemotherapy trials. BrJ Cancer. 1992;66(5):961-969.
70. Rooser B, Attewell R, Berg NO, Rydholm A. Survival in soft tissue sarcoma, prognostic variables identified by multivariate analysis. Acta Orthop Scand. 1987;58(5):516-522.
71. Sampo M, Tarkkanen M, Huuhtanen R, Tukiainen E, Bohling T, Blomqvist C. Impact of the smallest surgical margin on local control in soft tissue sarcoma. BrJ Surg. 2008;95(2):237-243.
72. Stefanovski PD, Bidoli E, De Paoli A, et al. Prognostic factors in soft tissue sarcomas: A study of 395 patients. Eur J Surg Oncol. 2002;28(2): 153-164.
73. Stoeckle E, Gardet H, Coindre JM, et al. Prospective evaluation of quality of surgery in soft tissue sarcoma. Eur J Surg Oncol. 2006;32(10): 1242-1248.
74. Wilson RB, Crowe PJ, Fisher R, Hook C, Donnellan MJ. Extremity soft tissue sarcoma: Factors predictive of local recurrence and survival. AustNZJ Surg. 1999;69(5):344-349.
75. Gadgeel SM, Harlan LC, Zeruto CA, Osswald M, Schwartz AG. Patterns of care in a population-based sample of soft tissue sarcoma patients in the united states. Cancer. 2009;115(12):2744-2754.
76. Le Doussal V, Coindre JM, Leroux A, et al. Prognostic factors for patients with localized primary malignant fibrous histiocytoma: A multicenter study of 216 patients with multivariate analysis. Cancer. 1996;77(9):1823-1830.
77. Kolovich GG, Wooldridge AN, Christy JM, Crist MK, Mayerson JL, Scharschmidt TJ. A retrospective statistical analysis of high-grade soft tissue sarcomas. Med Oncol. 2012;29(2): 1335-1344.
78. Merimsky O, Soyfer V, Kovner F, et al. Limb sparing approach: Adjuvant radiation therapy in adults with intermedi ate or high-grade limb soft tissue sarcoma. Radiother Oncol. 2005;77(3):295-300.
79. Delaney TF, Kepka L, Goldberg SI, et al. Radiation therapy for control of soft-tissue sarcomas resected with positive margins. IntJ Radiat Oncol Biol Phys. 2007;67(5):1460-1469.
80. Ipach I, Wingert T, Kunze B, Kluba T. Oncological outcome and prognostic factors in the therapy of soft tissue sarcoma of the extremities. Orthop Rev (Pavia). 2012;4(4):e34.
81. Alamanda VK, Crosby SN, Archer KR, Song Y, Schwartz HS, Holt GE. Predictors and clinical significance of local recurrence in extremity soft tissue sarcoma. Acta Oncol. 2012;52(4):793-802.
82. Dinges S, Budach V, Budach W, Feldmann HJ, Stuschke M, Sack H. Local recurrences of soft tissue sarcomas in adults: A retrospective analysis of prognostic factors in 102 cases after surgery and radiation therapy. EurJ Cancer. 1994; 30A(11): 1636-1642.
83. Khanfir K, Alzieu L, Terrier P, et al. Does adjuvant radiation therapy increase loco-regional control after optimal resection of soft-tissue sarcoma of the extremities? EurJ Cancer. 2003; 39(13): 1872-1880.
84. Mandard AM, Petiot JF, MarnayJ, et al. Prognostic factors in soft tissue sarcomas. A multivariate analysis of 109 cases. Cancer. 1989;63(7):1437-1451.
85. Singer S, Corson JM, Gonin R, Labow B, Eberlein TJ. Prognostic factors predictive of survival and local recurrence for extremity soft tissue sarcoma. Ann Surg. 1994;219(2):165-173.
86. Sampo M, Tarkkanen M, Tukiainen E, et al. A web-based prognostic tool for extremity and trunk wall soft tissue sarcomas and its external validation. BrJ Cancer. 2012; 106(6): 1076-1082.
87. Karakousis CP, Driscoll DL. Treatment and local control of primary extremity soft tissue sarcomas. J Surg Oncol. 1999; 71(3): 155-161.
88. Dickinson IC, Whitwell DJ, Battistuta D, et al. Surgical margin and its influence on survival in soft tissue sarcoma. ANZJ Surg. 2006;76(3): 104-109.
89. Gronchi A, Verderio P, De Paoli A, et al. Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall. Ann Oncol. 2013;24(3):817-823.
90. Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998; 16(1): 197-203.
91. Schreiber D, Rineer J, Katsoulakis E, et al. Impact of postoperative radiation on survival for high-grade soft tissue sarcoma of the extremities after limb sparing radical resection. Am J Clin Oncol. 2012;35(1): 13-17.
92. Edge S, Byrd DR, Comptom CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th edition. Springer; 2010.
93. Sobin LH, Gospodarowicz MK, Wittekind C. International union against cancer. TNM classification of malignant tumours. 7th edition. Wiley-Blackwell; 2009.
94. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;(153)(153):106-120.
95. Kaytan E, Yaman F, Cosar R, Eralp Y, Saip P, Darendeliler E. Prognostic factors in localized soft-tissue sarcomas. Am J Clin Oncol. 2003;26(4):411-415.
96. Lewis JJ, Leung D, Casper ES, Woodruff J, Hajdu SI, Brennan MF. Multifactorial analysis of long-term follow-up (morethan 5 years) of primary extremity sarcoma. Arch Surg. 1999; 134(2): 190-194.
97. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: A bad idea. Stat Med. 2006;25(1): 127-141.
98. Hollander N, Schumacher M. On the problem of using 'optimal' cutpoints in the assessment of quantitative prognostic factors. Onkologie. 2001;24(2):194-199.
99. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989;8(5):551-561.
100. Marrie RA, Dawson NV, Garland A. Quantile regression and restricted cubic splines are useful for exploring relationships between continuous variables. J Clin Epidemiol. 2009;62(5):511-517.
101. Royston P, Sauerbrei W. Multivariable modeling with cubic regression splines: A principled approach. Stata Journal. 2007;7(1):45-70.
102. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology. 1999;10(1):37-48.
103. Greenland S, Morgenstern H. Confounding in health research. Annu Rev Public Health. 2001;22:189-212.
104. Greenland S, Lash TL. Bias analysis. Modern Epidemiology. 2008:345-380.
105. Shrier I, Platt RW. Reducing bias through directed acyclic graphs. BMC Med Res Methodol. 2008;8:70-84.
106. Valderas JM, Starfield B, Sibbald B, Salisbury C, Roland M. Defining comorbidity: Implications for understanding health and health services. Ann Fam Med. 2009;7(4):357-363.
107. Piccirillo JF, Vlahiotis A, Barrett LB, Flood KL, Spitznagel EL, Steyerberg EW. The changing prevalence of comorbidity across the age spectrum. Crit Rev Oncol Hematol. 2008;67(2): 124-132.
108. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40(5):373-383.
109. Tetsche MS, Norgaard M, Skriver MV, Andersen ES, Lash TL, Sorensen HT. Accuracy of ovarian cancer ICD-10 diagnosis in a danish population-based hospital discharge registry. EurJ Gynaecol Oncol. 2005;26(3):266-270.
110. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53(12):1258-1267.
111. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8-27.
112. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am GeriatrSoc. 1968;16(5):622-626.
113. Greenfield S, Apolone G, McNeil BJ, Cleary PD. The importance of co-existent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement, comorbidity and outcomes after hip replacement. Med Care. 1993;31(2):141-154.
114. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity, a critical review of available methods. J Clin Epidemiol. 2003;56(3):221-229.
115. Piccirillo JF, Costas I. The impact of comorbidity on outcomes. ORL J Otorhinolaryngol RelatSpec. 2004;66(4):180-185.
116. Baldwin LM, Klabunde CN, Green P, Barlow W, Wright G. In search of the perfect comorbidity measure for use with administrative claims data: Does it exist? Med Care. 2006;44(8):745-753.
117. Reid BC, Alberg AJ, Klassen AC, et al. A comparison of three comorbidity indexes in a head and neck cancer population. Oral Oncol. 2002;38(2):187-194.
118. Piccirillo JF, Lacy PD, Basu A, Spitznagel EL. Development of a new head and neck cancer-specific comorbidity index. Arch Otolaryngol Head Neck Surg. 2002;128(10):1172-1179.
119. Boje CR, Dalton SO, Gronborg TK, et al. The impact of comorbidity on outcome in 12 623 danish head and neck cancer patients: A population based study from the DAHAN- CA database. Acta Oncol. 2013;52(2):285-293.
120. Iversen LH, Norgaard M, Jacobsen J, Laurberg S, Sorensen HT. The impact of comorbidity on survival of danish colorectal cancer patients from 1995 to 2006--a population-based cohort study. Dis Colon Rectum. 2009;52(1):71-78.
121. Tetsche MS, Dethlefsen C, Pedersen L, Sorensen HT, Norgaard M. The impact of comorbidity and stage on ovarian cancer mortality: A nationwide danish cohort study. BMC Cancer. 2008;8(1):31-39.
122. Grann AF, Froslev T, Olesen AB, Schmidt H, Lash TL. The impact of comorbidity and stage on prognosis of danish melanoma patients, 1987-2009: A registry-based cohort study. BrJ Cancer. 2013;109(1):265-271.
123. Lund L, Jacobsen J, Clark P, Borre M, Norgaard M. Impact of comorbidity on survival of invasive bladder cancer patients, 1996-2007: A danish population-based cohort study. Urology. 2009;75(2):393-398.
124. Lund L, Jacobsen J, Norgaard M, et al. The prognostic impact of comorbidities on renal cancer, 1995 to 2006: A danish population based study. J Urol. 2009;182(1):35-40.
125. Garbay D, Maki RG, Blay JY, et al. Advanced soft-tissue sarcoma in elderly patients: Patterns of care and survival. Ann Oncol. 2013;24(7): 1924-1930.
126. Lahat G, Dhuka AR, Lahat S, et al. Complete soft tissue sarcoma resection is a viable treatment option for select elderly patients. Ann Surg Oncol. 2009;16(9):2579-2586.
127. Matushansky I, Dela Cruz F, Insel BJ, Hershman DL, Neugut Al. Chemotherapy use in elderly patients with soft tissue sarcoma: A population-based study. Cancer Invest. 2013;31(2):83-91.
128. van Herk-Sukel MP, Shantakumar S, Overbeek LI, van Boven H, Penning-van Beest FJ, Herings RM. Occurrence of comorbidities before and after soft tissue sarcoma diagnosis. Sarcoma. 2012;2012(402109):l-7.
129. Nakamura T, Grimer R, Gaston C, et al. The value of C- reactive protein and comorbidity in predicting survival of patients with high grade soft tissue sarcoma. EurJ Cancer. 2013;49(2):377-385.
130. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89-95.
131. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6):448-454.
132. Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: Regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990; 12(5): 1179-1186.
133. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004; 113(9): 1271-1276
134. Nieken J, Mulder NH, Buter J, et al. Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. Blood. 1995;86(3):900-905.
135. Doshi SM, Shah P, Lei X, Lahoti A, Salahudeen AK. Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. Am J Kidney Dis. 2012;59(2):222-228.
136. Falkensammer CE, Thurnher M, Leonhartsberger N, Ramoner R. C-reactive protein is a strong predictor for anaemia in renal cell carcinoma: Role of IL-6 in overall survival. BJU Int. 2011; 107(12): 1893-1898.
137. Fox P, Hudson M, Brown C, et al. Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. BrJ Cancer. 2013;109(1):147-153.
138. Fujita K, Tanigawa G, Imamura R, et al. Preoperative serum sodium is associated with cancer-specific survival in patients with upper urinary tract urothelial carcinoma treated by nephroureterectomy. IntJ Urol. 2012;20(6):594-601.
139. Glynne-Jones R, Sebag-Montefiore D, Adams R, et al. Prognostic factors for recurrence and survival in anal cancer: Generating hypotheses from the mature outcomes of the first united kingdom coordinating committee on cancer research anal cancer trial (ACT I). Cancer. 2012;119(4):748-755.
140. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil- lymphocyte ratio: Experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88(1):218-230.
141. Hermes A, Waschki B, Reck M. Hyponatremia as prognostic factor in small cell lung cancer--a retrospective single institution analysis. Respir Med. 2012;106(6):900-904.
142. Huo TI, Lin HC, Hsia CY, et al. The MELD-na is an independent short- and long-term prognostic predictor for hepatocellular carcinoma: A prospective survey. Dig Liver Dis. 2008;40(11):882-889.
143. Kawashima A, Tsujimura A, Takayama H, et al. Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy. IntJ Urol. 2012; 19(12): 1050-1057.
144. Kim HS, Yi SY, Jun HJ, et al. Clinical outcome of gastric cancer patients with bone marrow metastases. Oncology. 2007;73(3-4): 192-197.
145. Lee H, Park HC, Park W, et al. Negative impact of pretreatment anemia on local control after neoadjuvant chemoradi- otherapy and surgery for rectal cancer. Radiat Oncol J. 2012;30(3): 117-123.
146. Obata J, Kikuchi E, Tanaka N, et al. C-reactive protein: A biomarker of survival in patients with localized upper tract urothelial carcinoma treated with radical nephroureterectomy. Urol Oncol. 2012;31(8):1725-1730.
147. Onate-Ocana LF, Aiello-Crocifoglio V, Gallardo-Rincon D, et al. Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann Surg Oncol. 2007;14(2):381-389.
148. Funovics PT, Edelhauser G, Funovics MA, et al. Pre-operative serum C-reactive protein as independent prognostic factor for survival but not infection in patients with high-grade osteosarcoma. Int Orthop. 2011;35(10):1529-1536.
149. Idowu OK, Ding Q, Taktak AF, Chandrasekar CR, Yin Q. Clinical implication of pretreatment neutrophil to lymphocyte ratio in soft tissue sarcoma. Biomarkers. 2012;17(6):539-544.
150. Michigan A, Johnson TV, Master VA. Preoperative C-reactive protein level adjusted for comorbidities and lifestyle factors predicts overall mortality in localized renal cell carcinoma. Mol Diagn Ther. 2011;15(4):229-234.
151. Nakamura T, Matsumine A, Matsubara T, Asanuma K, Uchida A, Sudo A. Clinical significance of pretreatment serum C- reactive protein level in soft tissue sarcoma. Cancer. 2012; 118(4): 1055-1061.
152. Nakamura T, Matsumine A, Matsubara T, Asanuma K, Uchida A, Sudo A. The combined use of the neutrophil-lymphocyte ratio and C-reactive protein level as prognostic predictors in adult patients with soft tissue sarcoma. J Surg Oncol. 2013;108(7):481-485.
153. Nakamura T, Grimer RJ, Gaston CL, Watanuki M, Sudo A, Jeys L. The prognostic value of the serum level of C-reactive protein for the survival of patients with a primary sarcoma of bone. Bone Joint J. 2013;95-B(3):411-418.
154. Nakanishi H, Araki N, Kudawara I, et al. Clinical implications of serum C-reactive protein levels in malignant fibrous histiocytoma. IntJ Cancer. 2002;99(2):167-170.
155. Szkandera J, Gerger A, Liegl-Atzwanger B, et al. Validation of the prognostic relevance of plasma C-reactive protein levels in soft-tissue sarcoma patients. BrJ Cancer. 2013;109(9):2316-2322.
156. Perez DR, Baser RE, Cavnar MJ, et al. Blood neutrophil-to- lymphocyte ratio is prognostic in gastrointestinal stromal tumor. Ann Surg Oncol. 2013;20(2):593-599.
157. Barreto-Andrade JC, Medina-Franco H. Serum albumin is an independent prognostic factor for survival in soft tissue sarcomas. Rev Invest Clin. 2009;61(3):198-204.
158. Nakamura T, Grimer R, Gaston C, et al. The relationship between pretreatment anaemia and survival in patients with adult soft tissue sarcoma. J Orthop Sci. 2013;18(6):987-993.
159. Aggerholm-Pedersen N, Rasmussen P, Dybdahl H, Rossen P, Nielsen OS, Safwat A. Serum natrium determines outcome of treatment of advanced GIST with imatinib: A retrospective study of 80 patients from a single institution. ISRN Oncol. 2011; 2011(523915): 1-7.
160. Behrendt N, Heegaard S, Fornitz GG. The hospital autopsy, an important factor in hospital quality assurance. Ugeskr Laeger. 1999;161(40):5543-5547.
161. Centers for Disease Control (CDC). Autopsy frequency- united states, 1980-1985. MMWR Morb Mortal Wkly Rep. 1988; 37(12): 191-194.
162. Eriksson L, Sundstrom C. Decreasing autopsy rate in Sweden reflects changing attitudes among clinicians. QualAssur Health Care. 1993;5(4):319-323.
163. Hoel DG, Ron E, Carter R, Mabuchi K. Influence of death certificate errors on cancer mortality trends. J Natl Cancer Inst. 1993;85(13): 1063-1068.
164. Smith Sehdev AE, Hutchins GM. Problems with proper completion and accuracy of the cause-of-death statement. Arch Intern Med. 2001;161(2):277-284.
165. Cameron HM, McGoogan E. A prospective study of 1152 hospital autopsies: I. inaccuracies in death certification. J Pathol. 1981; 133(4): 273-283.
166. Kircher T, Nelson J, Burdo H. The autopsy as a measure of accuracy of the death certificate. N Engl J Med. 1985; 313(20): 1263-1269.
167. Maclaine GD, Macarthur EB, Heathcote CR. A comparison of death certificates and autopsies in the australian capital territory. MedJAust. 1992;156(7):462-468.
168. Nielsen GP, Bjornsson J, Jonasson JG. The accuracy of death certificates, implications for health statistics. Virchows Arch A Pathol Anat Histopathol. 1991;419(2):143-146.
169. Welch HG, Black WC. Are deaths within 1 month of cancer- directed surgery attributed to cancer? J Natl Cancer Inst. 2002;94(14): 1066-1070.
170. Ederer F, Axtell LM, Cutler SJ. The relative survival rate: A statistical methodology. Natl Cancer Inst Monogr. 1961;6:101-121.
171. Sarfati D, Blakely T, Pearce N. Measuring cancer survival in populations: Relative survival vs cancer-specific survival. IntJ Epidemiol. 2010;39(2):598-610.
172. Ruka W, Rutkowski P, Kaminska J, Rysinska A, Steffen J. Alterations of routine blood tests in adult patients with soft tissue sarcomas: Relationships to cytokine serum levels and prognostic significance. Ann Oncol. 2001;12(10):1423-1432.
173. Szkandera J, Absenger G, Liegl-Atzwanger B, et al. Elevated preoperative neutrophil/lymphocyte ratio is associated with poor prognosis in soft-tissue sarcoma patients. BrJ Cancer. 2013; 108(8): 1677-1683.
174. Bray F, Engholm G, Hakulinen T, et al. Trends in survival of patients diagnosed with cancers of the brain and nervous system, thyroid, eye, bone, and soft tissues in the nordic countries 1964-2003 followed up until the end of 2006. Acta Oncol. 2010;49(5):673-693.
175. Stiller CA, Trama A, Serraino D, et al. Descriptive epidemiology of sarcomas in europe: Report from the RARECARE project. EurJ Cancer. 2013;49(3):684-695.
176. Ng VY, Scharschmidt TJ, Mayerson JL, Fisher JL. Incidence and survival in sarcoma in the united states: A focus on musculoskeletal lesions. Anticancer Res. 2013;33(6):2597-2604.
177. Guadagnolo BA, Zagars GK, Ballo MT, Strom SS, Pollock RE, Benjamin RS. Mortality after cure of soft-tissue sarcoma treated with conservation surgery and radiotherapy. Cancer. 2008;113(2):411-418.
178. Levi F, La Vecchia C, Randimbison L, Te VC. Descriptive epidemiology of soft tissue sarcomas in vaud, Switzerland. EurJ Cancer. 1999;35(12):1711-1716.
179. Storm HH. Survival of adult patients with cancer of soft tissues or bone in europe. EUROCARE working group. EurJ Cancer. 1998;34(14 Spec No):2212-2217.
180. Sant M, Allemani C, Santaquilani M, et al. EUROCARE-4. survival of cancer patients diagnosed in 1995-1999. results and commentary. EurJ Cancer. 2009;45(6):931-991.
181. Statistics Denmark. Population Denmark. http://www.dst.dk/en/Statistik/emner/befolkning-og-befolkningsfremskrivning/folketal.aspx.
182. Danish Health and Medicines Authority. Cancer pathways, soft tissue and bone sarcoma. http://Www.sst.dk/publ/Publ2012/06juni/KraeftPkforl/SarkomerKnogleBloeddele3udg.pdf.
183. Co-operative Cancer Departments. Treatment of sarcoma and aggressive benign tumors. http://www.ambkir.dk/Faglige%20retningslinier/Behandling%20af%20sarkomer.pdf.
184. Pedersen CB. The danish civil registration system. Scand J Public Health. 2011;39(7 Suppl):22-25.
185. The Danish Civil Registry. http://cpr.dk/cpr/site.aspx?p=194&ArticlelD=4326.
186. Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The danish cancer registry—history, content, quality and use. Dan Med Bull. 1997;44(5):535-539.
187. Lynge E, Sandegaard JL, Rebolj M. The danish national patient register. Scand J Public Health. 2011;39(7 Suppl):30-33.
188. Nickelsen TN. Data validity and coverage in the danish national health registry. A literature review. Ugeskr Laeger. 2001;164(1):33-37.
189. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The danish national hospital register. A valuable source of data for modern health sciences. Dan Med Bull. 1999;46(3):263-268.
190. Helweg-Larsen K. The danish register of causes of death. Scand J Public Health. 2011;39(7 Suppl):26-29.
191. Joint Committee on Nomenclature, Properties and Units (C- SC-NPU) of the IFCC and IUPAC, Pontet F, Magdal Petersen U, et al. Clinical laboratory sciences data transmission: The NPU coding system. Stud Health Techno! Inform. 2009;150:265-269.
192. Grann AF, Erichsen R, Nielsen AG, Froslev T, Thomsen RW. Existing data sources for clinical epidemiology: The clinical laboratory information system (LABKA) research database at aarhus university, denmark. Clin Epidemiol. 2011;3:133-138.
193. Reference values, Aarhus University hospital. http://www.auh.dk/om+auh/afdelinger/klinisk+biokemisk+afdeling/for+sundhedsfaglige/analysefortegnelse/nbg.
194. Rothman KJ. Epidemiology: An introduction. 2nd edition. Oxford: Oxford University Press; 2002:223.
195. Ahmad O, Boschi-Pinto C, Lopez A, Murray C, Lozano R, Inoue M. Age standardization of rates: A new WHO standard. http://www.who.int/healthinfo/paper31.pdf.
196. Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: Potential and pitfalls. BMJ. 2009;339:157-160.
197. Giorgi R, Belot A, Gaudart J, Launoy G, French Network of Cancer Registries FRANCIM. The performance of multiple imputation for missing covariate data within the context of regression relative survival analysis. Stat Med. 2008; 27(30):6310-6331.
198. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011;30(4):377-399.
199. Fletcher RH, Fletcher SW, Fletcher GS. Clinical epidemiology: The essentials. 5th edition. Lippincott Williams & Wilkins; 2012.
200. Fletcher CDM, Unni KK, Mertens F. Pathology and genetics, tumours of soft tissue and bone. (WHO classification of tumours, volume 5). 3rd edition. Lyon: IARC Press; 2002:427.
201. Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F. WHO classification of tumours of soft tissue and bone. 4th edition. Lyon: IARC Press; 2013:427.
202. Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sorensen HT. The predictive value of ICD-10 diagnostic coding used to assess charlson comorbidity index conditions in the population-based danish national registry of patients. BMC Med Res Methodol. 2011;11:83-88.
203. Textor J, Liskiewicz M. Adjustment criteria in causdal diagrams: An algorithmic perspective. Proceedings ofthe 27th Conference on Uncertainty in Artificial Intelligence. 2011:681-688.
204. Textor J, Hardt J, Knuppel S. DAGitty: A graphical tool for analyzing causal diagrams. Epidemiology. 2011;22(5):745.
205. Guay B, Johnson-Obaseki SE, McDonald JT, Connell C, Cor-sten M. Incidence of differentiated thyroid cancer by socioeconomic status and urban residence: Canada 1991-2006. Thyroid. 2014;24(3):552-5.
206. Hwang E, Johnson-Obaseki S, McDonald JT, Connell C, Cor- sten M. Incidence of head and neck cancer and socioeconomic status in Canada from 1992 to 2007. Oral Oncol. 2013;49(11): 1072-6.
207. Parise CA, Caggiano V. Disparities in race/ethnicity and socioeconomic status: Risk of mortality of breast cancer patients in the California cancer registry, 2000--2010. BMC Cancer. 2013;13(1):449.
208. Schmeisser N, Conway Dl, Stang A, et al. A population-based case-control study on social factors and risk of testicular germ cell tumours. BMJ Open. 2013;3(9):l-8.
209. Siu S, McDonald JT, Rajaraman M, et al. Is lower socioeconomic status associated with more advanced thyroid cancer stage at presentation? A study in two Canadian centers. Thyroid. 2014; 24(3): 545-51.
210. Park HS, Lloyd S, Decker RH, Wilson LD, Yu JB. Overview of the surveillance, epidemiology, and end results database: Evolution, data variables, and quality assurance. Curr Probl Cancer. 2012;36(4):183-190.
211. Maguire A, Porta M, Malats N, Gallen M, Pinol JL, Fernandez E. Cancer survival and the duration of symptoms, an analysis of possible forms of the risk function. ISDS II project investigators. EurJ Cancer. 1994;30(6):785-792.
212. O’sullivan B, Pisters PW. Staging and prognostic factor evaluation in soft tissue sarcoma. Surg Oncol Clin N Am. 2003;12(2):333-353.
213. Castillo JJ, Vincent M, Justice E. Diagnosis and management of hyponatremia in cancer patients. Oncologist. 2012;17(6):756-765.
214. Jensen AR, Game JP, Storm HH, Engholm G, Moller T, Over- gaard J. Does stage at diagnosis explain the difference in survival after breast cancer in denmark and Sweden? Acta Oncol. 2004;43(8):719-726.
215. Mork J, Glattre E. Squamous cell carcinomas of the head and neck in norway, 1953-92: An epidemiologic study of a low- risk population. Cancer Causes Control. 1998;9(l):37-48.
216. Mocellin S, Nitti D. Gastrointestinal carcinoid: Epidemiological and survival evidence from a large population-based study (n = 25 531). Ann Oncol. 2013;24(12):3040-3044.
217. Waxman AJ, Mink PJ, Devesa SS, et al. Racial disparities in incidence and outcome in multiple myeloma: A population- based study. Blood. 2010;116(25):5501-5506.
218. Tarantino I, Achermann P, Guller U, et al. Relative survival is an adequate estimate of cancer-specific survival: Baseline mortality-adjusted 10-year survival of 771 rectal cancer patients. Ann Surg Oncol. 2013;20(12):3877-3884.
219. Cervantes F, Dupriez B, Passamonti F, et al. Improving survival trends in primary myelofibrosis: An international study. J Clin Oncol. 2012;30(24):2981-2987.
220. Johnson CJ, Weir HK, Fink AK, et al. The impact of national death index linkages on population-based cancer survival rates in the united states. Cancer Epidemiol. 2013;37(1):20-28.
221. Hu CY, Xing Y, Cormier JN, Chang GJ. Assessing the utility of cancer-registry-processed cause of death in calculating cancer-specific survival. Cancer. 2013;119(10):1900-1907.